LaennecAI
LaennecAI is a Cardiff-based medical technology startup transforming smartphones into digital stethoscopes. Our AI-driven solution detects and interprets early abnormal respiratory sounds, preventing exacerbations and improving patient outcomes.
Share profile
Problem
We address the critical need for early detection of respiratory conditions, such as asthma, which currently lack reliable home-care tools. Without early detection, patients often experience delayed treatments, leading to increased emergency hospital visits and poor health outcomes. Our technology enables timely identification of abnormal respiratory sounds, helping to prevent exacerbations and reduce the burden on healthcare systems.
Solution
Business Model
USP
Vision
Target Market
LaennecAI transforms smartphones into digital stethoscopes using advanced AI to detect and interpret abnormal respiratory sounds early. Our user-friendly app provides actionable insights, guiding users to timely care and preventing exacerbations. This innovative, cost-effective solution enhances patient self-management, reduces emergency hospital visits, improves overall health outcomes, and eases the burden on healthcare systems.
LaennecAI operates on a dual business model. B2C: Users subscribe to our digital stethoscope app, providing accessible, high-quality healthcare. B2B2C: We leverage strategic NHS partnerships for R&D and market validation, and generate additional revenue by licensing our technology through API and SDK integrations with telemedicine platforms and health services, ensuring seamless integration and broad market reach.
Our AI-driven digital stethoscopes transform smartphones into powerful diagnostic tools, combining advanced sound detection with intelligent interpretation. This cost-effective, software-based solution provides early detection and actionable insights. Backed by a strategic NHS partnership, we empower users to manage respiratory conditions proactively, reducing healthcare burdens and improving patient outcomes. This sets us apart from traditional stethoscopes and other digital solutions.
Our long-term vision is to revolutionise healthcare by making advanced diagnostics accessible to everyone through smartphones. We aim to expand our technology to cover a wide range of respiratory and cardiac conditions globally. By continuously innovating and partnering with healthcare providers, including the NHS, we strive to improve patient outcomes, reduce healthcare costs, and empower individuals to take control of their health through preventive care.
Our primary target market includes individuals with asthma, focusing on both children and adults (5.4 million in the UK). Our digital stethoscope technology enables early detection and management of respiratory sounds, preventing exacerbations. Additionally, our solution adapts to other respiratory and cardiac conditions (15 million), like COPD and atrial fibrillation. We target consumers through subscriptions and partnerships with telemedicine platforms and the NHS.
Disclaimer
Investing is a high-risk activity. Foundercentre is a networking platform and in no way solicits or recommends any opportunity presented on our website. All information is for educational purposes only.
